US9707245B2ActiveUtilityA1

Neridronic acid for treating complex regional pain syndrome

98
Assignee: ANTECIP BIOVENTURES II LLCPriority: May 14, 2012Filed: Nov 21, 2016Granted: Jul 18, 2017
Est. expiryMay 14, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Herriot Tabuteau
A61K 31/675A61K 31/663A61K 9/2004A61K 9/0019A61K 9/0053
98
PatentIndex Score
42
Cited by
441
References
30
Claims

Abstract

Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method of treating pain associated with complex regional pain syndrome (CRPS) comprising administering neridronic acid to a human being with CRPS, wherein bone fracture was a predisposing event for CRPS, and wherein the neridronic acid is in a salt or an acid form. 
     
     
       2. The method of  claim 1 , wherein the CRPS is CRPS type I. 
     
     
       3. The method of  claim 1 , wherein the neridronic acid is in a salt form. 
     
     
       4. The method of  claim 1 , wherein the neridronic acid is administered intravenously. 
     
     
       5. The method of  claim 1 , wherein the neridronic acid is administered orally. 
     
     
       6. The method of  claim 5 , wherein a total of about 50 mg to about 500 mg of the neridronic acid is administered daily. 
     
     
       7. The method of  claim 5 , wherein a total of about 100 mg to about 500 mg of the neridronic acid is administered daily. 
     
     
       8. The method of  claim 5 , wherein a total of about 150 mg to about 300 mg of the neridronic acid is administered daily. 
     
     
       9. The method of  claim 1 , wherein the neridronic acid is administered parenterally. 
     
     
       10. The method of  claim 9 , wherein a total of about 5 mg to about 500 mg of the neridronic acid is administered within one month. 
     
     
       11. The method of  claim 9 , wherein a total of about 5 mg to about 200 mg of the neridronic acid is administered within one month. 
     
     
       12. The method of  claim 9 , wherein each dose contains about 10 mg to about 150 mg of the neridronic acid. 
     
     
       13. The method of  claim 9 , wherein a total of about 100 mg to about 300 mg of the neridronic acid is administered within one month. 
     
     
       14. The method of  claim 1 , wherein a total of about 100 mg to about 600 mg of the neridronic acid is administered. 
     
     
       15. The method of  claim 1 , wherein a total of about 100 mg to about 300 mg of the neridronic acid is administered. 
     
     
       16. The method of  claim 4 , wherein each dose contains about 10 mg to about 150 mg of the neridronic acid. 
     
     
       17. The method of  claim 4 , wherein each dose contains about 100 mg of the neridronic acid. 
     
     
       18. The method of  claim 17 , wherein the neridronic acid is administered at least four times. 
     
     
       19. The method of  claim 4 , wherein each dose contains about 50 mg to about 65 mg of the neridronic acid. 
     
     
       20. The method of  claim 19 , wherein the neridronic acid is administered about every three days. 
     
     
       21. The method of  claim 5 , wherein each dose contains about 100 mg of the neridronic acid. 
     
     
       22. The method of  claim 3 , wherein each dose contains an equivalent of about 50 mg to about 60 mg of the neridronic acid. 
     
     
       23. The method of  claim 1 , wherein the neridronic acid is administered about once daily to about once weekly. 
     
     
       24. The method of  claim 1 , wherein the neridronic acid is administered in a single or in divided doses. 
     
     
       25. The method of  claim 21 , wherein about four doses of about 100 mg of the neridronic acid are administered. 
     
     
       26. The method of  claim 1 , wherein the neridronic acid is administered weekly for about four to about six weeks. 
     
     
       27. The method of  claim 1 , wherein the human being is at least 18 years of age. 
     
     
       28. The method of  claim 27 , wherein the human being is at least 40 years of age. 
     
     
       29. The method of  claim 27 , wherein the human being has a baseline pain intensity score of at least 4 on the 0-10 Numeric Rating Scale. 
     
     
       30. The method of  claim 1 , wherein the CRPS is CRPS type II.

Join the waitlist — get patent alerts

Track US9707245B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.